Concerned about the shortage of exit opportunities for impact investments?
Here’s one: Early-stage impact investing network Investors’ Circle announced an exit from its portfolio this week, as Boston Heart Diagnostics, a US-based health services firm with a proprietary blood test was acquired by Luxembourg-based Eurofins Scientific for $140 million.
“We were compelled by the social mission of saving lives, the well-conceived business model, and an attractive valuation,” said Sky Lance, Investors’ Circle member and managing principal of the Patient Capital Collaborative fund. Investors’ Circle has deployed $185 million into more than 290 companies.
